KRAS and non-small cell lung carcinoma: In a study on early-stage NSCLC (n = 179), mKRAS G12C was associated with poor DFS (p = 0.006) compared with KRAS-WT; however, the statistical strength of this analysis dropped significantly for stage I patients, suggesting the influence of pathological stage on DFS [49].